NSAIDs in Head and Neck Cancer Bring New Meaning to Precision Medicine
Patients with PIK3CA-altered head and neck cancers lived longer if they took NSAIDs, suggesting old drugs may have new clinical uses.
Head and Neck Cancer
HEAD AND NECK CANCER ADVISOR
FEATURED CONTENT
-
-
Active Surveillance: Is it an Appropriate Approach for Thyroid Cancer?
In patients with thyroid cancer, active surveillance has been controversial because surgery is the standard of care. -
Predicting PD-1/PD-L1 Immunotherapy Responses
Finding biomarkers that can broadly and reliably predict immunotherapy outcomes for patients with cancer remains an elusive “holy grail,” said Dr Ott. -
Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
Concerns about conflict of interest as it relates to prescribing may never go away, some say, as long as drug companies offer doctors money for consulting and personal services. -
Opinion: Understanding the FDA’s Take on Cannabidiol
In a statement announcing a newly created partnership, the Botanical Safety Consortium, FDA Commissioner Scott Gottlieb made no mention of cannabidiol.
HEAD AND NECK CANCER NEWS
Gene Signature Predicts Outcomes in HPV-Related Oropharyngeal Cancers
Consequences of HPV-Related Disparities in Head and Neck Cancer
Hybrid Minimally Invasive Esophagectomy Confers Lower Complication Rate
Liquid Biopsy of Cerebrospinal Fluid Provides Genomic Info on Brain Tumors
ASCO Critiques Guideline for HPV Testing in Head and Neck Cancer
MORE HEAD AND NECK CANCER INFORMATION
KEYTRUDA (pembrolizumab) for Head and Neck Cancer
ERBITUX (cetuximab) for Head and Neck Cancer and Colorectal Cancer
Want to read more?
Please login or register first to view this content.
Next post in Uncategorized
